A CCR2 antagonist (PF-04136309) also suppresses macrophage accumulation in the primary tumor developed by orthotopically injected pancreatic cancer cells, which enhances the effects of gemcitabine on the tumor growth [45]. This evidence concerns the gene CCR2 and neoplasm.